ReviewRadiology2022
How We Do It: Managing the Indeterminate Renal Mass with the MRI Clear Cell Likelihood Score.
Review in Radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Diagnostic performance of contrast enhancement to differentiate benign and malignant renal lesions in CT and MRI: a systematic review and meta-analysis of diagnostic test accuracy (DTA) studies.Abdominal radiology (New York) · 2025Pooled it
- Pre-operative imaging evaluation of renal cell carcinoma.Revista da Associacao Medica Brasileira (1992) · 2024Guideline
- Systematic review and meta-analysis of multiparametric MRI clear cell likelihood scores for classification of small renal masses.Frontiers in oncology · 2022Pooled it
- Head-to-head comparison of quantitative perfusion parameters derived from DECT, IVIM, and DCE-MRI for renal mass characterization: a within-patient, prospective study.Abdominal radiology (New York) · 2026Article
- Added diagnostic value of pseudocapsule and ADC heterogeneity beyond ccLS v2.0 in small renal masses.Abdominal radiology (New York) · 2026Article
- Staging and imaging-based prognostication in renal cell carcinoma: current guidelines and practical considerations.Abdominal radiology (New York) · 2026Review
- MRI-based habitat radiomics for assessing synchronous metastatic risk in renal cell carcinoma: a multicenter study.Abdominal radiology (New York) · 2026Article
- MRI enhancement characteristics of septa and walls improve risk stratification of Bosniak III cystic renal masses.Abdominal radiology (New York) · 2026Article
- Estimating the Sodium Content: A Case Series of Benign and Malignant Renal Tumours UsingNMR in biomedicine · 2026Article
- Combined radiological approach for characterization of solid renal masses: a proposed strategy for integrating the RENAL nephrometry score into the clear cell likelihood score.BMC medical imaging · 2026Article
- Renal CT algorithm for evaluating clear cell carcinoma in solid renal masses ≤ 4 cm: a retrospective chinese two-center validation study.Abdominal radiology (New York) · 2026Article
- Reply to the Letter to the Editor: Diagnostic performance of the clear cell likelihood score integrated with cystic degeneration or necrosis on MR imaging for identifying clear cell renal cell carcinoma in cT1 solid renal masses.Insights into imaging · 2026Article
- Article
- Multimodal deep learning model for multiclass classification of renal tumors.NPJ digital medicine · 2026Article
- Diagnostic performance of the clear cell likelihood score (ccLS) for small renal masses characterization in patients undergoing percutaneous biopsy.La Radiologia medica · 2026Article
- Modified clear cell likelihood score and a new CAT score in the assessment of indeterminate small renal masses.Journal of cancer research and clinical oncology · 2026Article
- Evaluation, Optimization, and Validation of a Multiparametric CT Algorithm for Solid Renal Masses: CT-Score Version 2.0.Radiology. Imaging cancer · 2026Article
- Immuno-oncologic profiling of renal masses using multiparametric MRI: a pilot study.Journal for immunotherapy of cancer · 2025Article
- Advances in renal cancer: diagnosis, treatment, and emerging technologies.La Radiologia medica · 2025Review
- Peritumoral Cortex Low-Enhancement Sign on Corticomedullary Phase CT: A Distinctive Indicator of Small Renal Malignancies.Korean journal of radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The widespread use of cross-sectional imaging has led to a continuous increase in the number of incidentally detected indeterminate renal masses. Frequently, these clinical scenarios involve an older patient with comorbidities and a small renal mass (≤4 cm). Despite aggressive treatment in early stages of the disease, a clear positive effect in reducing kidney cancer-specific mortality is lacking, indicating that many renal cancers exhibit an indolent oncologic behavior. Furthermore, in general, one in five small renal masses is histologically benign and may not benefit from aggressive treatment. Although active surveillance is increasingly recognized as a management option for some patients, the absence of reliable clinical and imaging predictive biologic markers of aggressiveness can contribute to patient anxiety and limit its use in clinical practice. A standardized approach to the image interpretation of solid renal masses has not been broadly implemented. The clear cell likelihood score (ccLS) derived from multiparametric MRI is useful in noninvasively identifying the clear cell subtype, the most common and aggressive form of kidney cancer. Herein, a review of the ccLS is presented, including a step-by-step guide for image interpretation and additional guidance for its implementation in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.